Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-03-16 4:19 pm Sale | 13D | Aptinyx Inc. APTX | Longitude Capital Partners II LLC | 192,805 0.3% | -3,451,746 (-94.71%) | View |
| 2023-02-14 4:31 pm Purchase | 13D | Aptinyx Inc. APTX | Longitude Capital Partners II LLC | 3,644,551 5.4% | 137,807 (+3.93%) | View |
| 2023-02-14 4:17 pm Sale | 13G | Rapid Micro Biosystems, Inc. RPID | Longitude Capital Partners II LLC | 4,189,845 11.3% | -2,702 (-0.06%) | View |
| 2023-02-14 4:15 pm Sale | 13D | Kala Pharmaceuticals, Inc. KALA | Longitude Capital Partners II LLC | 108,239 6.3% | -5,348,791 (-98.02%) | View |
| 2023-01-03 5:04 pm Sale | 13D | Venus Concept Inc. VERO | Longitude Capital Partners II LLC | 3,466,118 5% | -225,231 (-6.10%) | View |
| 2022-02-14 6:38 pm Purchase | 13G | Rapid Micro Biosystems, Inc. RPID | Longitude Capital Partners II LLC | 4,192,547 12.2% | 4,192,547 (New Position) | View |
| 2021-08-13 5:15 pm Purchase | 13D | RxSight, Inc. RXST | Longitude Capital Partners II LLC | 2,506,972 9.1% | 2,506,972 (New Position) | View |
| 2021-02-12 5:12 pm Purchase | 13G | Vaxcyte, Inc. PCVX | Longitude Capital Partners II LLC | 3,108,780 6.1% | 3,108,780 (New Position) | View |
| 2020-03-23 5:00 pm Purchase | 13D | Kala Pharmaceuticals, Inc. KALA | Longitude Capital Partners II LLC | 5,457,030 10% | 2,561,664 (+88.47%) | View |
| 2020-02-12 4:34 pm Purchase | 13D | Aptinyx Inc. APTX | Longitude Capital Partners II LLC | 3,506,744 8% | 316,665 (+9.93%) | View |
| 2020-02-12 4:32 pm Purchase | 13G | Nabriva Therapeutics plc NBRV | Longitude Capital Partners II LLC | 4,256,527 4.5% | 244,152 (+6.08%) | View |
| 2020-02-12 4:24 pm Purchase | 13G | Aimmune Therapeutics Inc. AIMT | Longitude Capital Partners II LLC | 6,215,278 9.8% | 23,750 (+0.38%) | View |
| 2019-11-18 4:21 pm Purchase | 13D | Venus Concept Inc. VERO | Longitude Capital Partners II LLC | 3,691,349 12.4% | 3,691,349 (New Position) | View |
| 2019-02-12 5:07 pm Purchase | 13G | Aimmune Therapeutics Inc. AIMT | Longitude Capital Partners II LLC | 6,191,528 10% | 33,093 (+0.54%) | View |
| 2018-10-12 4:19 pm Purchase | 13D | Kala Pharmaceuticals, Inc. KALA | Longitude Capital Partners II LLC | 2,895,366 9% | 616,860 (+27.07%) | View |
| 2018-08-07 4:51 pm Purchase | 13G | Nabriva Therapeutics plc NBRV | Longitude Capital Partners II LLC | 4,012,375 6% | 4,012,375 (New Position) | View |
| 2018-07-06 4:15 pm Purchase | 13D | Tricida Inc. TCDA | Longitude Capital Partners II LLC | 3,021,924 7.2% | 3,021,924 (New Position) | View |
| 2018-07-02 5:26 pm Purchase | 13D | Aptinyx Inc. APTX | Longitude Capital Partners II LLC | 3,190,079 9.5% | 3,190,079 (New Position) | View |